Alamar Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
ALMR$31.50-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets(Unaudited, in thousands)
| September 30,2026 · December 31,2025 | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash and cash equivalents | $ | 121,532 | $ | 30,002 |
| Short-term investments | 105,053 | — | ||
| Accounts receivable | 21,611 | 12,753 | ||
| Inventory | 54,133 | 38,482 | ||
| Prepaid expenses and other current assets | 15,359 | 13,468 | ||
| Total current assets | 317,688 | 94,705 | ||
| Restricted cash | 4,907 | 4,907 | ||
| Property and equipment, net | 15,244 | 10,498 | ||
| Operating lease right-of-use assets | 36,236 | 26,130 | ||
| Capitalized software, net | 1,443 | 1,988 | ||
| Other assets—noncurrent | 2,509 | 1,764 | ||
| Total assets | $ | 378,027 | $ | 139,992 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||
| Current Liabilities | ||||
| Accounts payable | $ | 16,549 | $ | 5,872 |
| Accrued and other current liabilities | 14,450 | 15,759 | ||
| Short-term operating lease liabilities | 2,483 | 2,099 | ||
| Total current liabilities | 33,482 | 23,730 | ||
| Long-term operating lease liabilities | 39,867 | 29,564 | ||
| Warrant liabilities | — | 247 | ||
| Term debt | — | 9,810 | ||
| Other noncurrent liabilities | 974 | 599 | ||
| Total liabilities | 74,323 | 63,950 | ||
| Convertible preferred stock | — | 234,996 | ||
| Stockholders’ equity (deficit) | ||||
| Founders preferred stock | — | — | ||
| Common stock | 7 | 1 | ||
| Additional paid-in capital | 520,511 | 9,892 | ||
| Accumulated other comprehensive loss | (173) | (72) | ||
| Accumulated deficit | (216,641) | (168,775) | ||
| Total stockholders’ equity (deficit) | 303,704 | (158,954) | ||
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $ | 378,027 | $ | 139,992 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.